307 related articles for article (PubMed ID: 16784736)
21. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
Tomita Y; Maeda K; Sugiyama Y
Clin Pharmacol Ther; 2013 Jul; 94(1):37-51. PubMed ID: 23443754
[TBL] [Abstract][Full Text] [Related]
22. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.
Tomlinson B; Hu M; Lee VW; Lui SS; Chu TT; Poon EW; Ko GT; Baum L; Tam LS; Li EK
Clin Pharmacol Ther; 2010 May; 87(5):558-62. PubMed ID: 20130569
[TBL] [Abstract][Full Text] [Related]
23. [Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers].
Sui SM; Wen JH; Li XH; Xiong YQ
Yao Xue Xue Bao; 2011 Jun; 46(6):695-700. PubMed ID: 21882531
[TBL] [Abstract][Full Text] [Related]
24. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
[TBL] [Abstract][Full Text] [Related]
25. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.
Deng JW; Shon JH; Shin HJ; Park SJ; Yeo CW; Zhou HH; Song IS; Shin JG
Pharm Res; 2008 Aug; 25(8):1807-14. PubMed ID: 18236139
[TBL] [Abstract][Full Text] [Related]
26. Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil.
Bergman E; Lundahl A; Fridblom P; Hedeland M; Bondesson U; Knutson L; Lennernäs H
Drug Metab Dispos; 2009 Dec; 37(12):2349-58. PubMed ID: 19773540
[TBL] [Abstract][Full Text] [Related]
27. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
Kitamura S; Maeda K; Wang Y; Sugiyama Y
Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
[TBL] [Abstract][Full Text] [Related]
28. Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus.
He L; Yang Y; Guo C; Yao D; Liu HH; Sheng JJ; Zhou WP; Ren J; Liu XD; Pan GY
Eur J Pharmacol; 2014 Feb; 724():185-92. PubMed ID: 24342797
[TBL] [Abstract][Full Text] [Related]
29. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
30. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
31. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
[TBL] [Abstract][Full Text] [Related]
32. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Keskitalo JE; Kurkinen KJ; Neuvonen M; Backman JT; Neuvonen PJ; Niemi M
Br J Clin Pharmacol; 2009 Aug; 68(2):207-13. PubMed ID: 19694740
[TBL] [Abstract][Full Text] [Related]
33. Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.
Tanaka Y; Kitamura Y; Maeda K; Sugiyama Y
J Pharm Sci; 2015 Sep; 104(9):3039-48. PubMed ID: 25639366
[TBL] [Abstract][Full Text] [Related]
34. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
[TBL] [Abstract][Full Text] [Related]
35. Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of rosuvastatin in human plasma: application to a pharmacokinetic study.
Gao J; Zhong D; Duan X; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Sep; 856(1-2):35-40. PubMed ID: 17560178
[TBL] [Abstract][Full Text] [Related]
36. Determinants of gefitinib pharmacokinetics in healthy Chinese male subjects: A pharmacogenomic study of cytochrome p450 enzymes and transporters.
Wan Z; Guo L; Li P; Zhao Z; Xu B; Ren L; Yan Y; Liu H; Zhang Y; Liu L
J Clin Pharm Ther; 2020 Oct; 45(5):1159-1167. PubMed ID: 32562509
[TBL] [Abstract][Full Text] [Related]
37. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.
Hu M; To KK; Mak VW; Tomlinson B
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):49-62. PubMed ID: 21091277
[TBL] [Abstract][Full Text] [Related]
38. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Brindley C; Short T
Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
[TBL] [Abstract][Full Text] [Related]
39. Effect of food on the pharmacokinetics of rosuvastatin after administration of a single oral dose in dogs.
Baek IH; Kwon KI; Kim MS
Drug Res (Stuttg); 2013 Mar; 63(3):145-9. PubMed ID: 23447089
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
Martin PD; Mitchell PD; Schneck DW
Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
